

Leukaemia Section

Short Communication

del(6q) abnormalities in lymphoid malignancies

Christophe Brigaudeau, Chrystele Bilhou-Nabera

Laboratory of Hematology, University Hospital, 87000 Limoges, France (CB); Laboratoire d'Hématologie, Hôpital du Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac, France (CBN)

Published in Atlas Database: December 1998


Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/del6qID1148.html>
DOI: 10.4267/2042/37487

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note

Deletion of the long arm of chromosome 6 (del(6q)) is more frequently described in lymphoid proliferations than in other hematological malignancies; del(6q) is observed in acute lymphoblastic leukemia (ALL), in chronic lymphocytic leukemia (CLL), in prolymphocytic leukemia and in non-Hodgkin lymphomas (NHL) (15% cases, sometimes associated with t(14;18)(q32;q21)); these deletions are mainly reported to be terminal, but also interstitial.



del(6q) - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at the Waisman Center; R-banding (right) – Editor.

Clinics and pathology

Disease

Childhood B-cell acute lymphoblastic leukemia (B-ALL)

Phenotype/cell stem origin

Lack of specificity for a particular immunophenotype.

Epidemiology

Found in 5-15% of patients after conventional cytogenetic analysis, in 30% after FISH analysis, in 5 to 25% of cases in loss of heterozygosity studies.

Prognosis

Not significantly different from patients lacking a 6q rearrangement.

Disease

Childhood T-cell acute lymphoblastic leukemia (T-ALL)

Epidemiology

del(6q) is one of the most frequent cytogenetic aberration occurring in 10-20% of cases and often associated with 14q11 or del(9p) abnormalities.

Prognosis

Outcome similar to cases with normal diploid karyotypes.

Disease

Adult acute lymphoblastic leukemia

Phenotype/cell stem origin

T-cell phenotype found in 50% of cases (ALL).

Epidemiology

del(6q) in adult-ALL occur with a lower frequency (5%) than in children and is reported predominantly in young adult (15 to 40 years aged).

Prognosis

Patients with a 6q change tented to have longer event free survival (EFS) (median: 11 months; 3

years EFS: 47%) than did patients without 6q changes (median EFS: 7 month; 3 years EFS: 20%).

Disease

B-cell small lymphocytic lymphoma

Epidemiology

del(6)(q21q23) is the most common recurrent cytogenetic abnormality in this disease.

Clinics

In cases with del(6q), a morphological appearance of peripheral blood large prolymphocytes, a mature B-cell phenotype and a typical clinical course of other well-differentiated lymphocytic neoplasms are described.

Disease

Atypical chronic lymphocytic leukemia

Prognosis

Complex karyotypes with +12, del(13)(q14), del(11q), del(6)(q21q23) and possible 4q or 10q anomalies are associated with a poor prognosis.

Disease

Multiple myeloma

Phenotype/cell stem origin

Multiple myeloma (MM) is a malignant plasma cell proliferation of mature differentiated B-cell.

Epidemiology

del (6q) in multiple myeloma represent 15% of cases of MM.

Prognosis

del(6q) are more frequent in the hypodiploid group of multiple myeloma, bearing a worse prognosis (med survival of 1.5 yr).

Cytogenetics

Cytogenetics morphological

The frequency of the deletions is difficult to estimate by conventional cytogenetic analysis because small interstitial deletions are beyond the sensitivity of the technique; furthermore, many studies have reported conflicting data on the putative region of overlap and the number of region involved; the break occurs predominantly in 6q21, but 6q15 is also often described; overall, del(6q) cases encompassed the 6q21 band.

in acute lymphoblastic leukemia (ALL), del(6q) is the sole anomaly in about 30% of cases, or associated with other structural abnormalities such as del(12p) (early pre-B ALL), del(9p) (B and T-cell immunophenotype), specific aberrations, such as t(4;11), t(1;19), t(9;22), t(12;21) or with random chromosomal changes.

Genes involved and proteins

Note

6q21 band loss suggests the presence of a recessive tumour suppressor gene whose absence might contribute to malignant transformation and development of both T and precursor B-ALLs; the lack of specificity for a particular immunophenotype may imply that the gene or genes affected by 6q abnormalities are broadly active in the multistep process of lymphoid leukemogenesis.

Putative tumour suppressor gene(s) on chromosome arm 6q remains to be identified; to demonstrate this loss of heterozygosity of informative markers (LOH) was analysed using PCR amplification of polymorphic microsatellite sequences; using polymorphic markers located from the 6q14-15 to telomere, LOH was detected in 5 to 25% of childhood ALL cases.

Regarding LOH results, two distinct regions were identified:

- first region flanked by D6S283 and D6S302 loci at 6q21-22

- second region flanked by D6S275 and D6S283 loci at 6q21.

Using LOH analysis on several cases, the authors demonstrated an identical 6q21-22 structure at diagnosis and at relapse, suggesting that 6q deletion may be an initial event in leukemogenesis and may occur less frequently during progression of the disease.

References

Hayashi Y, Raimondi SC, Look AT, Behm FG, Kitchingman GR, Pui CH, Rivera GK, Williams DL. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. *Blood*. 1990 Oct 15;76(8):1626-30

Offit K, Louie DC, Parsa NZ, Filippa D, Gangi M, Siebert R, Chaganti RS. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). *Blood*. 1994 May 1;83(9):2611-8

Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. *Blood*. 1996 Apr 15;87(8):3135-42

Cavé H, Guidal C, Elion J, Vilmer E, Grandchamp B. A low rate of loss of heterozygosity is found at many different loci in childhood B-lineage acute lymphocytic leukemia. *Leukemia*. 1996 Sep;10(9):1486-91

Bigoni R, Cuneo A, Roberti MG, Bardi A, Rigolin GM, Piva N, Scapoli G, Spanedda R, Negrini M, Bullrich F, Veronese ML, Croce CM, Castoldi G. Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. *Leukemia*. 1997 Nov;11(11):1933-40

Gérard B, Cavé H, Guidal C, Dastugue N, Vilmer E, Grandchamp B. Delineation of a 6 cM commonly deleted region in childhood acute lymphoblastic leukemia on the 6q chromosomal arm. *Leukemia*. 1997 Feb;11(2):228-32

Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. *Br J Haematol*. 1997 Mar;96(3):601-10

Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report

from the Children's Cancer Group. *J Clin Oncol*. 1998 Apr;16(4):1270-8

Merup M, Moreno TC, Heyman M, Rönnerberg K, Grandér D, Detlofsson R, Rasool O, Liu Y, Söderhäll S, Juliusson G, Gahrton G, Einhorn S. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. *Blood*. 1998 May 1;91(9):3397-400

Takeuchi S, Koike M, Seriu T, Bartram CR, Schrappe M, Reiter A, Park S, Taub HE, Kubonishi I, Miyoshi I, Koeffler HP. Frequent loss of heterozygosity on the long arm of chromosome 6: identification of two distinct regions of deletion in childhood acute lymphoblastic leukemia. *Cancer Res*. 1998 Jun 15;58(12):2618-23

This article should be referenced as such:

Brigaudeau C, Bilhou-Nabera C. del(6q) abnormalities in lymphoid malignancies. *Atlas Genet Cytogenet Oncol Haematol*. 1999; 3(1):33-35.
